1
Michellys Pierre Yves, Pei Wei, Marsilje Thomas H, Lu Wenshuo, Chen Bei, Uno Tetsuo, Jin Yunho, Jiang Tao: Compounds and compositions as protein kinase inhibitors. Irm, Michellys Pierre Yves, Pei Wei, Marsilje Thomas H, Lu Wenshuo, Chen Bei, Uno Tetsuo, Jin Yunho, Jiang Tao, TONGCO WU Emily, June 19, 2008: WO/2008/073687 (58 worldwide citation)

The invention provides novel pyrimidine and pyridine derivatives of formula (I) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds ...


2
Choi Ha Soon, Wang Zhicheng, Gray Nathanael Schiander, Gu Xiang Ju, He Xiaohui, He Yun, Jiang Tao, Liu Yi, Richmond Wendy, Sim Taebo, Yang Kunyong: Compounds and compositions as protein kinase inhibitors. Irm, Choi Ha Soon, Wang Zhicheng, Gray Nathanael Schiander, Gu Xiang Ju, He Xiaohui, He Yun, Jiang Tao, Liu Yi, Richmond Wendy, Sim Taebo, Yang Kunyong, REID Scott W, September 1, 2005: WO/2005/080393 (43 worldwide citation)

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal act ...


3
Gray Nathanael S, Michellys Pierre Yves, Pei Wei, Marsilje Thomas H, Lu Wenshuo, Chen Bei, Uno Tetsuo, Jin Yunho, Jiang Tao: (het) Arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors. Irm, Gray Nathanael S, Michellys Pierre Yves, Pei Wei, Marsilje Thomas H, Lu Wenshuo, Chen Bei, Uno Tetsuo, Jin Yunho, Jiang Tao, TONGCO WU Emily, March 12, 2009: WO/2009/032703 (39 worldwide citation)

This invention relates to novel amino substituted pyrimidine compounds of formula (I), pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other act ...


4
Mi Yuan, Pan Shifeng, Gray Nathanael S, Gao Wenqi, Fan Yi, Jiang Tao: Immunosuppressant compounds and compositions. Irm, Mi Yuan, Pan Shifeng, Gray Nathanael S, Gao Wenqi, Fan Yi, Jiang Tao, REID Scott, January 6, 2005: WO/2005/000833 (29 worldwide citation)

The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particul ...


5
Marsilje Thomas H, Gray Nathanael S, Jiang Tao, Lu Wenshuo, Pan Shifeng: Immunosuppressant compounds and compositions. Irm, Marsilje Thomas H, Gray Nathanael S, Jiang Tao, Lu Wenshuo, Pan Shifeng, REID Scott W, December 2, 2004: WO/2004/103309 (19 worldwide citation)

The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particul ...


6
Jiang Tao, Tsien Roger Y: Peptides whose uptake by cells is controllable. The Regent Of The University Of California, Jiang Tao, Tsien Roger Y, PARENT Annette S, May 12, 2005: WO/2005/042034 (14 worldwide citation)

A generic structure for the peptides of the present invention includes A - X - B -C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; howe ...


7
Grote Christopher W, Wang Peter X, Jiang Tao, Cantrell Gary L, Moser Frank W, Thomasson Catherine E: Improved process for the preparation of 6-alpha-hydroxy-n-alkylated opiates. Mallinckrodt, Grote Christopher W, Wang Peter X, Jiang Tao, Cantrell Gary L, Moser Frank W, Thomasson Catherine E, SIMAN Craig D, November 13, 2008: WO/2008/137672 (13 worldwide citation)

The present invention is directed to the conversion of a 6-keto morphinan to a 6-alpha-hydroxy morphinan in the presence of a ruthenium, rhodium, or iridium asymmetric catalyst and a hydrogen source.


8
Chen Bei, Jiang Tao, Marsilje Thomas H, Michellys Pierre Yves, Nguyen Truc Ngoc, Pei Wei, Wu Baogen, Gao Zhaobo, Ge Yonghui, Huang Chen, Li Yuncheng: Compounds and compositions as protein kinase inhibitors. Irm, Novartis, Chen Bei, Jiang Tao, Marsilje Thomas H, Michellys Pierre Yves, Nguyen Truc Ngoc, Pei Wei, Wu Baogen, Gao Zhaobo, Ge Yonghui, Huang Chen, Li Yuncheng, sTONGO WU Emily, October 15, 2009: WO/2009/126515 (13 worldwide citation)

The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kina ...


9
He Yun, Ellis David Archer, Anaclerio Beth Marie, Kuhen Kelli L, Wu Baogen, Jiang Tao: Quinolones with anti-hiv activity. Irm, He Yun, Ellis David Archer, Anaclerio Beth Marie, Kuhen Kelli L, Wu Baogen, Jiang Tao, MANN Jeffry S, May 6, 2004: WO/2004/037853 (12 worldwide citation)

The present invention relates to inhibition of viruses, e.g., HIV using quinolones and compounds related to quinolones. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of proph ...


10
Jiang Tao, Olson Emilia S, Whitney Michael, Aguilera Todd, Nguyen Quyen, Wong Edmund, Tsien Roger Y: Peptides whose uptake by cells is controllable. The Regents Of The University Of California, Jiang Tao, Olson Emilia S, Whitney Michael, Aguilera Todd, Nguyen Quyen, Wong Edmund, Tsien Roger Y, PARENT Annette S, November 23, 2006: WO/2006/125134 (10 worldwide citation)

A generic structure for the peptides of the present invention includes A – X – B - C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; how ...